IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today the appointment of three new members to its Medical Advisory Board.
Prof. Fabrice Andre, MD, PhD, Prof. Nadia Harbeck, MD, PhD and Prof. David Rimm, MD, PhD will join Dr. William Audeh, MD, Chief Medical Officer at Agendia, and Dr. Gabriel N. Hortobagyi, MD, FACP, FASCP, Medical Advisory Board Chair, who joined the Board earlier in 2016.
“On the heels of the publication of the MINDACT study, Agendia is well-positioned as a leader in the molecular diagnostic industry. As such, the company needs an advisory team that represents the best minds and reputations of the international breast cancer community,” said Dr. Gabriel N. Hortobagyi. “These new appointments will allow Agendia to stay at the forefront of breast cancer diagnostic technology.”
The MINDACT study was recently published in the New England Journal of Medicine. MINDACT was a collaboration between Agendia, the European Organization for Research and Treatment of Cancer (EORTC) and the Breast International Group (BIG). A unique phase III prospective, randomized, controlled study of 6,693 patients recruited across 112 European cancer centers, the MINDACT trial showed that 46% of breast cancer patients considered for chemotherapy, whose tumors were classified MammaPrint Low Risk, had excellent survival without chemotherapy, and could thus be candidates to avoid this toxic therapy.
The trial provided the highest level of clinical evidence (Level 1A) and confirmed the clinical utility of using Agendia’s MammaPrint 70-gene breast cancer recurrence assay to help predict clinical outcome in women with early-stage breast cancer.
“We are pleased to welcome these new members to the Agendia Board,” said Dr. William Audeh. “At such a crucial time in the company’s history, Agendia is proud to have such an outstanding team of physicians, who have dedicated their lives to the advancement of cancer treatment, available to help guide the company.”
Prof. Fabrice André, MD, PhD
Prof. Fabrice André is currently Professor in the Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. He received his MD in Grenoble in 2002, and a PhD in Biotechnology from Paris University in 2005. He is a past recipient of Young Investigator and Career Development awards from the American Society of Clinical Oncology (ASCO). Professor André is conducting research in the field of biomarkers and personalized therapies. His research work focuses on biomarker discovery, development of targeted agents and implementation of personalized medicine.
Prof. Nadia Harbeck, MD, PhD
Prof. Harbeck heads the breast center and holds the chair for Conservative Oncology at the Department for OB&GYN of the University of Munich (LMU), Germany. Prof. Harbeck is Scientific Director of the West German Study Group and was an executive board member of the European Organisation for Research and Treatment of Cancer (EORTC) (2009-2015). She is principal investigator or steering committee member of numerous national and international clinical breast cancer trials, focusing on trials using novel targeted compounds. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumors.
Prof. David L. Rimm, MD, PhD
Dr. David Rimm is a Professor in the Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine. He is the Director of Yale Pathology Tissue Services. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. His research lab group focuses on quantitative pathology using the AQUA® technology invented in his lab with projects related to predicting response to therapy or recurrence in cancer.
For more information on Agendia’s Medical Advisory Board or its suite of breast cancer products, visit the Agendia newsroom: http://www.agendia.com/agendia-news-and-press-releases/.
Follow Agendia, Inc. on Facebook, Twitter, or LinkedIn to keep up-to-date with the latest news.
MammaPrint is a FDA-cleared in vitro diagnostic test, available from FFPE sample, performed in a single laboratory, using the gene expression profile of breast cancer tissue samples to assess a patients' risk for distant metastasis. The MammaPrint result is indicated for use by physicians as a prognostic marker only, along with other clinical-pathological factors. MammaPrint is not intended for diagnosis, or to predict or detect response to therapy, or to help select the optimal therapy for patients. Results should be taken in the context of other relevant clinical-pathological factors and standard practice of medicine.
Agendia is a privately held, leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Our offerings include the FDA-cleared MammaPrint FFPE 70-gene breast cancer recurrence assay as well as BluePrint®, a molecular subtyping assay that provides deeper insight leading to more clinically actionable breast cancer biology. These tests can help physicians assess a patient’s individual risk for metastasis – that is, which patients are more sensitive to chemo, hormonal, or combination therapy, and which patients may not require these treatments and which patients may be treated with other, less arduous and costly methods.
In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology. For more information, visit www.agendia.com.